OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer

Core Points - OSE Immunotherapeutics received a positive recommendation from the Independent Data Monitoring Committee (IDMC) to continue the Phase 3 ARTEMIA trial evaluating Tedopi® in non-small cell lung cancer (NSCLC) without modifications [1][3][4] - The ARTEMIA trial, launched in September 2024, aims to compare Tedopi® monotherapy to standard-of-care docetaxel in HLA-A2 positive patients with metastatic NSCLC who have developed secondary resistance to immune checkpoint inhibitors [3][4] - As of early October, 102 patients had been randomized in the trial, with recruitment expected to reach 120, aligning with enrollment projections for 2025 [3] - A second IDMC review is anticipated in Q1 2026, with completion of recruitment expected by the end of 2026 and primary endpoint readout for overall survival projected for Q1 2028 [4] Company Overview - OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases [1][5] - The company collaborates with leading academic institutions and biopharmaceutical companies to develop transformative medicines for serious diseases [5] - OSE Immunotherapeutics is based in Nantes and Paris and is listed on Euronext [5]